What is Unipolar Depression?
Unipolar depression, also known as major depressive disorder (MDD), is a severe mood disorder characterized by depressed mood, loss of interest in activities, and associated psychological and somatic symptoms lasting at least 2 weeks, without episodes of mania or hypomania (which would indicate bipolar disorder). 1
The term "unipolar" distinguishes this condition from bipolar disorder—patients experience only depressive episodes, not the manic or hypomanic episodes seen in bipolar spectrum disorders. This affects approximately 9% of US adults annually, with lifetime prevalence of 17% for men and 30% for women 1.
Diagnostic Criteria
Diagnosis should follow ICD-10 or DSM criteria and include:
- Depressed mood or loss of interest/pleasure
- At least 2 weeks duration
- Associated symptoms: significant weight/appetite changes, sleep disturbance, psychomotor changes, fatigue, worthlessness/guilt, concentration difficulties, recurrent thoughts of death 2
- Structured severity assessment using tools like PHQ-9 or HAM-D 2
- Screen for suicide risk, bipolar features, psychotic symptoms, substance use, and anxiety comorbidity 1
First-Line Treatment Options
For Mild Depression:
Watchful waiting for 14 days is appropriate initially 3. If treatment is needed, psychotherapy alone is preferred over medication, as side effects often outweigh benefits in mild cases 4.
For Moderate Depression:
Both psychotherapy and pharmacotherapy are equally effective first-line options—choose based on patient preference, availability, and adverse effect profiles 5, 3.
Psychotherapy Options (all have medium-to-large effect sizes):
- Cognitive Behavioral Therapy (CBT)
- Behavioral activation
- Interpersonal therapy
- Problem-solving therapy
- Brief psychodynamic therapy
- Mindfulness-based psychotherapy
Network meta-analysis shows these produce standardized mean differences of 0.50-0.73 over usual care 1.
Pharmacotherapy - Second-Generation Antidepressants:
Select based on adverse effect profiles, cost, and patient preferences—not efficacy, as all are similarly effective 5. All 21 studied antidepressants show small-to-medium effects (SMD 0.23-0.48) over placebo 1.
Preferred agents:
- SSRIs (selective serotonin reuptake inhibitors) are first-line, with sertraline having particular advantages 6
- Bupropion has lower sexual dysfunction rates than SSRIs 5
- Avoid paroxetine due to higher sexual dysfunction rates 5
Critical monitoring: Assess patient status within 1-2 weeks of initiation for suicidal ideation, agitation, or behavioral changes, as SSRIs increase risk of suicide attempts versus placebo 5.
For Severe Depression:
Combination of antidepressant medication plus psychotherapy is recommended 3. Network meta-analysis demonstrates combined treatment produces greater symptom improvement than either psychotherapy alone (SMD 0.30) or medication alone (SMD 0.33) 1.
Treatment Duration and Maintenance
Continue treatment for 4-9 months after achieving remission for first episode 5. For patients with 2+ prior episodes, continue maintenance treatment for at least 2 years to prevent recurrence 3, 4.
Second-Line Strategies for Treatment-Resistant Depression
If inadequate response after 6-8 weeks at adequate doses 5:
Three equally effective options exist:
- Switch to different antidepressant
- Add second antidepressant
- Augment with lithium (strongest evidence for augmentation) 3
Avoid combining multiple antidepressants without trying lithium augmentation first 3.
Common Pitfalls to Avoid
- Do not use antidepressant monotherapy if bipolar disorder is suspected—this can trigger manic episodes 7
- Do not discontinue treatment prematurely—38% don't respond by 6-12 weeks, and 54% don't achieve remission, requiring patience and strategy adjustments 5
- Do not ignore metabolic monitoring—newer antidepressants have better tolerability than tricyclics, but monitoring remains important 8
- Do not assume all patients prefer medication—patients often prefer psychotherapy when given the choice 9
Collaborative Care Improves Outcomes
Systematic follow-up and outcome assessment through collaborative care programs significantly improves treatment effectiveness (SMD 0.42 vs usual care) 1. This structured approach addresses the reality that 60.8% of patients require a second treatment trial, 33.7% a third, and 17.1% a fourth 10.